Sigmund Brabrand

  • Consultant; MD, PhD

Main project: exome sequencing of bilateral tumors

Testicular germ cell tumors (TGCT) evolve from a premalignant precursor, intratubular germ cell neoplasia (ITGCNU). However, the etiology and time of malignant transformation remain enigmatic. A striking resemblance between ITGCNU and the immature phenotype of primordial germ cells (PGCs) indicate that malignant transformation occurs early in embryogenesis. Between embryonic week 5th and 6th the PGCs migrate through the embryo before the pool of cells separate and colonize the precursor of the gonads. It is unknown whether the malignant transformation occurs prior to or after this separation

In this project, we will perform exome sequencing of cancer and normal DNA from patients with bilateral TGCT, to clarify if malignant transformation of PGCs occurs prior to or after the separation of PGCs. We hypothesize that if malignant transformation and associated somatic mutations in PGCs occur at a pre-separation stage, it would reflect in identical somatic mutations in subsequent bilateral TGCTs. As exome sequencing data from TGCT has not yet been published, we will provide novel insight into the mutational landscape of this cancer type.

 

Academic degrees:

2005-2009: Clinical education in medical oncology and radiotherapy

2004: Norwegian doctor certification

1996-2002: Candidatus Medicinae (MD)

 

Publications 2022

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045

Publications 2018

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241

Publications 2015

Brabrand S, Johannessen B, Axcrona U, Kraggerud SM, Berg KG, Bakken AC, Bruun J, Fosså SD, Lothe RA, Lehne G, Skotheim RI (2015)
Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages
Neoplasia, 17 (2), 167-74
DOI 10.1016/j.neo.2014.12.005, PubMed 25748235

Publications 2012

Brabrand S, Fosså SD, Cvancarova M, Axcrona U, Lehne G (2012)
Probability of metachronous testicular cancer in patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell cancer
J Clin Oncol, 30 (32), 4004-10
DOI 10.1200/JCO.2011.40.8914, PubMed 23071246

Publications 2010

Brabrand S, Fosså SD, Cvancarova M, Lehne G (2010)
Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals
BJU Int, 107 (7), 1080-7
DOI 10.1111/j.1464-410X.2010.09649.x, PubMed 20825398

Publications 2005

Holt RU, Baykov V, Rø TB, Brabrand S, Waage A, Sundan A, Børset M (2005)
Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor
Haematologica, 90 (4), 479-88
PubMed 15820943

Publications 2002

Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Børset M, Waage A, Nordic Myeloma Study Group (2002)
Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy
Br J Haematol, 119 (3), 672-6
DOI 10.1046/j.1365-2141.2002.03898.x, PubMed 12437643

Page visits: 2524